Jiangsu vcare pharmaceutical technology co., LTD
This is a randomized, double-blind, dose-escalating, placebo-controlled phase Ib clinical study.
Rheumatoid Arthritis
VC005 tablets
VC005 Tablets Placebo
Phase 1
Study Type : | Interventional |
Estimated Enrollment : | 30 participants |
Masking : | Double |
Primary Purpose : | Treatment |
Official Title : | A Randomized, Double-blind, Dose-escalating, Placebo-controlled Phase Ib Clinical Study of VC005 Tablets in Subjects With Rheumatoid Arthritis. |
Actual Study Start Date : | June 12, 2023 |
Estimated Primary Completion Date : | October 18, 2023 |
Estimated Study Completion Date : | October 25, 2023 |
Arm | Intervention/treatment |
---|---|
Experimental: VC005 Tablets Low Dose groups |
Drug: VC005 tablets |
Experimental: VC005 Tablets Medium Dose groups |
Drug: VC005 tablets |
Experimental: VC005 Tablets High Dose groups |
Drug: VC005 tablets |
Experimental: VC005 Tablets Placebo Low Dose groups |
Drug: VC005 Tablets Placebo |
Experimental: VC005 Tablets Placebo Medium Dose groups |
Drug: VC005 Tablets Placebo |
Experimental: VC005 Tablets Placebo High Dose groups |
Drug: VC005 Tablets Placebo |
Ages Eligible for Study: | 18 Years to 70 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
The First Bethune Hospital of Jilin University
Changchun, Jilin, China, 130061